```
============================================================
Sequence Listing was accepted with existing errors.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: Wed May 23 12:25:26 EDT 2007
============================================================
```

Validated By CRFValidator v 1.0.2

Application No: 10580164   Version No: 1.1

Input Set:

Output Set:

Started:	2007-05-23 12:25:14.656
Finished:	2007-05-23 12:25:14.731
Elapsed:	0 hr(s) 0 min(s) 0 sec(s) 75 ms
Total Warnings:	0
Total Errors:	0
No. of SeqIDs Defined:	4
Actual SeqID Count:	4

<110>   Christie, Mark Ian
        Mead, Richard James
        Robinson, Martyn Kim
        Rapecki, Stephen Edward

<120>   METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING
        IL-17 ACTIVITY

<130>   CELL-0316

<140>   10/580,164
<141>   2006-05-18

<150>   PCT/GB2004/004850
<151>   2004-11-16

<150>   GB 0417115.3
<151>   2004-07-30

<150>   GB 0327181.4
<151>   2003-11-21

<160>   4

<170>   PatentIn version 3.3

<210>   1
<211>   103
<212>   PRT
<213>   Homo sapiens

<400>   1

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1   5   10   15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20   25   30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35   40   45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50   55   60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65   70   75   80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85   90   95

Lys Val Glu Pro Lys Ser Cys
            100

<210> 2
<211> 108
<212> PRT
<213> Homo sapiens

<400> 2

Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
1   5   10   15

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
            20   25   30

Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
        35   40   45

Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
    50   55   60

Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
65   70   75   80

Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
            85   90   95

Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
            100   105

<210> 3
<211> 101
<212> PRT
<213> Mus musculus

<400> 3

Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala
1   5   10   15

Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
            20   25   30

Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly

```
                 35                      40                        45

Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
    50                      55                    60


Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr
65                      70                    75                    80


Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
                85                    90                    95


Val Pro Arg Asp Cys
            100



<210>   4
<211>   105
<212>   PRT
<213>   Mus musculus

<400>   4

Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu
1                   5                   10                    15


Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro
                20                    25                    30


Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn
            35                    40                    45


Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr
    50                      55                    60


Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His
65                      70                    75                    80


Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile
                85                    90                    95


Val Lys Ser Phe Asn Arg Gly Glu Cys
            100                   105
```